A Pill for Sleep Apnea? Inside the Push Toward Personalized Treatment

By Dr. Chelsie Rohrscheib, Ph.D. — Last reviewed: May 15, 2026 · 6 min read

Key Takeaways

• Sulthiame is an investigational oral medication for obstructive sleep apnea that works by stabilizing the body’s breathing control during sleep — a fundamentally different mechanism than CPAP.
• In the FLOW study, a 15-week multicenter randomized trial, Sulthiame produced dose-dependent reductions in breathing disturbances and improvements in nighttime oxygen levels in adults with moderate to severe OSA.
• Sulthiame is not yet FDA-approved or available in the United States.
• If approved, it would most likely benefit patients who cannot tolerate CPAP — particularly those with unstable ventilatory control.
• Continuous home-based monitoring will be essential for evaluating who responds to pharmacologic therapy.

Obstructive sleep apnea (OSA) is one of the most common yet underdiagnosed chronic conditions worldwide. It is characterized by repeated collapse of the upper airway during sleep, leading to intermittent hypoxia, frequent arousals, and profound physiological stress on the body. Over time, untreated OSA increases the risk of hypertension, cardiovascular disease, stroke, metabolic dysfunction, and cognitive impairment [1–3]. Despite its serious health consequences, many patients remain untreated — not because therapies do not exist, but because the most effective therapy is often difficult to use consistently.

Continuous positive airway pressure (CPAP) has long been the gold standard for treating OSA. By delivering a steady stream of air that keeps the airway open, CPAP can effectively eliminate breathing disturbances when used properly. However, adherence remains a persistent challenge, with many patients struggling to tolerate the mask, pressure, or overall experience of sleeping with a device. Even using standard adherence definitions, such as at least four hours per night on most nights, a substantial proportion of patients fall short of consistent use [4–6]. This gap between efficacy and adherence has driven decades of research into alternative therapies.

A New Mechanism: Meet Sulthiame

Now, a new investigational medication is generating attention as a potential addition to the sleep apnea treatment landscape. Sulthiame, an oral drug studied in a recent randomized controlled trial, represents a fundamentally different approach to managing OSA. Rather than mechanically preventing airway collapse, it targets the body’s control of breathing itself.

In a multicenter, double-blind, placebo-controlled study of adults with moderate to severe OSA, Sulthiame demonstrated dose-dependent reductions in breathing disturbances and improvements in overnight oxygenation over a 15-week period [7]. These findings suggest that pharmacologic therapy may be able to meaningfully reduce disease severity in at least a subset of patients. However, what makes Sulthiame particularly interesting is not just its efficacy signal — it is its mechanism.

Sulthiame is a carbonic anhydrase inhibitor, a class of compounds that alters acid-base balance and increases respiratory drive. In simple terms, it appears to stabilize the body’s breathing control system during sleep. OSA is often thought of as a purely anatomical problem — a narrow or collapsible airway — but decades of research have shown that physiology plays a major role. Some patients have unstable ventilatory control, meaning their breathing system overcorrects in response to changes in oxygen and carbon dioxide levels, contributing to repetitive airway collapse [8–10]. By increasing baseline respiratory drive and reducing this instability, Sulthiame may help prevent the cascade of events that leads to obstructive events in certain individuals.

This distinction is critical. CPAP works by physically splinting the airway open. Sulthiame, by contrast, may work by making the airway less likely to collapse in the first place. These are not competing mechanisms — they are complementary ones. And that raises the possibility of a more personalized approach to treatment, where therapy is matched to the underlying physiology of the patient.

What We Do Not Yet Know

That said, it is important to be clear: Sulthiame is not yet available in the United States. As of now, it remains an investigational therapy, with clinical development ongoing. Larger and longer-term studies will be required to confirm its safety, durability, and effectiveness across diverse patient populations before it can be considered for regulatory approval [11]. While the early data are promising, this is not an immediate replacement for existing therapies.

Who Might Benefit Most

So who might benefit most from a medication like this? Based on current evidence, the most likely candidates are adults with moderate to severe OSA who are unable or unwilling to use CPAP consistently. More specifically, patients whose disease is driven in part by unstable ventilatory control, rather than purely anatomical obstruction, may derive the greatest benefit. Importantly, this does not mean that pharmacologic therapy will replace CPAP, oral appliances, weight loss, or surgical interventions. Instead, it may expand the toolbox, offering another option for patients who currently have limited alternatives.

The New Measurement Challenge

But the introduction of drug therapy into sleep medicine raises an equally important question: how will we measure whether it is working? Unlike a one-night intervention, a medication requires ongoing evaluation. Clinicians will need to assess baseline disease severity, monitor early response to treatment, evaluate dose adjustments, and track long-term outcomes. This is where home-based sleep testing and longitudinal monitoring become essential.

Technologies like Wesper Lab are well suited to support this shift. By enabling multi-night, real-world assessment of sleep apnea severity, oxygenation, and physiological patterns, home testing platforms can help identify which patients are most likely to respond to pharmacologic therapy and objectively track their progress over time. In a future where OSA is treated more like other chronic diseases, continuous monitoring — not just a single diagnostic study — will be critical for optimizing care.

A Broader Transformation

The emergence of Sulthiame signals something larger than the development of a single drug. It reflects a broader transformation in how we think about sleep apnea — not as a one-size-fits-all condition treated with a single device, but as a complex, multifactorial disorder that may require individualized therapy.

CPAP will remain an essential and highly effective treatment for many patients. But for those who cannot tolerate it, the possibility of an oral medication offers something the field has long needed: another path forward.

If these early findings are borne out in future trials, the next era of sleep medicine may not be defined by a single breakthrough, but by a more flexible, personalized approach — one that combines pharmacology, devices, and data-driven monitoring to meet patients where they are.

Frequently Asked Questions

Is there a pill for sleep apnea?

Not yet on the U.S. market, but the first investigational drug to meaningfully reduce sleep apnea severity is in clinical development. Sulthiame, studied in the FLOW trial, produced dose-dependent reductions in breathing disturbances over 15 weeks in adults with moderate to severe obstructive sleep apnea.

What is Sulthiame and how does it work for sleep apnea?

Sulthiame is a carbonic anhydrase inhibitor — a class of medication that increases respiratory drive and stabilizes the body’s breathing control during sleep. Rather than physically holding the airway open like CPAP, Sulthiame appears to make airway collapse less likely by reducing ventilatory instability.

Will Sulthiame replace CPAP?

No. CPAP remains highly effective for patients who can tolerate it. Sulthiame, if approved, is more likely to expand the treatment toolbox — particularly for patients who cannot tolerate CPAP or whose sleep apnea is driven by ventilatory control issues rather than airway anatomy alone.

Is Sulthiame FDA-approved?

No. As of 2026, Sulthiame is an investigational therapy in clinical development. It has not received FDA approval and is not commercially available in the United States.

Who would benefit most from a sleep apnea pill?

Based on current evidence, the most likely candidates are adults with moderate-to-severe OSA who cannot or will not use CPAP consistently — and especially those whose disease is partly driven by unstable ventilatory control.

How will doctors know if a sleep apnea medication is working?

Unlike a one-night sleep study, evaluating drug therapy requires ongoing assessment. Home-based, multi-night sleep testing platforms can track changes in sleep apnea severity, oxygenation, and breathing patterns over time — making continuous monitoring essential for evaluating pharmacologic response.

---

References

1. Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol. 2013;177(9):1006–14.
2. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med. 1993;328(17):1230–5.
3. Marin JM, Carrizo SJ, Vicente E, Agusti AGN. Long-term cardiovascular outcomes in men with obstructive sleep apnea-hypopnea with or without treatment with continuous positive airway pressure: an observational study. Lancet. 2005;365(9464):1046–53.
4. Weaver TE, Grunstein RR. Adherence to continuous positive airway pressure therapy. Proc Am Thorac Soc. 2008;5(2):173–8.
5. Rotenberg BW, Murariu D, Pang KP. Trends in CPAP adherence over twenty years of data collection: a flattened curve. Sleep Med. 2016;25:78–83.
6. American Academy of Sleep Medicine. Clinical guidelines for the use of positive airway pressure devices in adults with obstructive sleep apnea. Darien (IL): American Academy of Sleep Medicine; 2019.
7. Hedner J, et al. Sultiame once per day in obstructive sleep apnoea (FLOW): a multicentre, randomised, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet. 2025.
8. Eckert DJ. Phenotypic approaches to obstructive sleep apnoea – new pathways for targeted therapy. Am J Respir Crit Care Med. 2018;197(5):559–70.
9. Wellman A, Malhotra A, Jordan AS, Stevenson KE, Gautam S, White DP. Ventilatory control and loop gain in obstructive sleep apnea. J Appl Physiol (1985). 2004;97(3):1309–16.
10. Edwards BA, White DP, Malhotra A. Pathophysiology of obstructive sleep apnea beyond anatomy. Chest. 2010;138(2):330–8.
11. U.S. Food and Drug Administration. The drug development process. Silver Spring (MD): FDA; cited 2026 Mar 19.

---

Author: Dr. Chelsie Rohrscheib, Ph.D., Wesper.